NYSE - Nasdaq Real Time Price • USD
AbbVie Inc. (ABBV)
As of 12:56 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 19 | 19 | 22 | 22 |
| Avg. Estimate | 3.05 | 2.9 | 11.24 | 12.06 |
| Low Estimate | 2.99 | 2.81 | 11.02 | 11.4 |
| High Estimate | 3.11 | 2.98 | 11.4 | 12.71 |
| Year Ago EPS | 2.91 | 2.95 | 11.11 | 11.24 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 16 | 23 | 23 |
| Avg. Estimate | 14.02B | 14.17B | 55.2B | 58.34B |
| Low Estimate | 13.88B | 13.98B | 54.89B | 56.43B |
| High Estimate | 14.2B | 14.37B | 55.84B | 60.81B |
| Year Ago Sales | 13.87B | 13.71B | 54.32B | 55.2B |
| Sales Growth (year/est) | 1.10% | 3.40% | 1.60% | 5.70% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 2.81 | 2.86 | 2.77 | 2.23 |
| EPS Actual | 2.91 | 2.95 | 2.79 | 2.31 |
| Difference | 0.1 | 0.09 | 0.02 | 0.08 |
| Surprise % | 3.60% | 3.10% | 0.70% | 3.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 3.05 | 2.9 | 11.24 | 12.06 |
| 7 Days Ago | 3.05 | 2.9 | 11.25 | 12.05 |
| 30 Days Ago | 3.06 | 2.9 | 11.26 | 12.07 |
| 60 Days Ago | 2.81 | 2.93 | 11.21 | 12.22 |
| 90 Days Ago | 2.81 | 2.92 | 11.19 | 12.21 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | ABBV | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 4.80% | -- | -- | 9.10% |
| Next Qtr. | -1.70% | -- | -- | 11.50% |
| Current Year | 1.20% | -- | -- | 5.70% |
| Next Year | 7.30% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 6.21% | -- | -- | 11.34% |
| Past 5 Years (per annum) | 5.57% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | HSBC: Hold to Buy | 6/5/2024 |
| Initiated | Cantor Fitzgerald: Overweight | 5/17/2024 |
| Maintains | Barclays: Overweight to Overweight | 4/29/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 4/29/2024 |
| Maintains | Barclays: Overweight to Overweight | 3/27/2024 |
| Maintains | Guggenheim: Buy to Buy | 3/22/2024 |
Related Tickers
JNJ Johnson & Johnson
146.06
-0.69%
PFE Pfizer Inc.
28.04
-1.89%
MRK Merck & Co., Inc.
130.19
-0.37%
BMY Bristol-Myers Squibb Company
41.95
+1.12%
AMGN Amgen Inc.
302.07
-0.97%
LLY Eli Lilly and Company
860.86
+1.28%
GILD Gilead Sciences, Inc.
64.27
-0.66%
AZN AstraZeneca PLC
80.36
+0.42%
GSK GSK plc
41.15
-0.16%
NVS Novartis AG
105.10
-0.22%